Meds like Wegovy are all over the news. But are they right for you, especially if you’re older than the average user?
Zepbound outperformed Wegovy for weight loss in a new clinical trial funded by Eli Lilly & Co., Zepbound's maker.
Despite this escalating demand for popular GLP-1 drugs, the prices for some of these products are actually dropping. Dr.
Eli Lilly just shared some new information. That data suggests it has an advantage against Novo Nordisk in a key market.
People are reporting that their weight-loss medication helps them steer clear of drugs and alcohol. Studies are promising, ...
The biotech disclosed Friday plans to terminate a Phase 2 study testing azelaprag with tirzepatide for weight loss following ...
Patients self-administer the drug using a pre-dosed injector pen, but Lilly recently introduced the product in single-dose ...
The European Commission granted unconditional approval to Novo Holdings’ $16.5 billion takeover of Catalent, a decision both ...
The top China executive of US pharmaceutical company Eli Lilly and Co said on Wednesday that the company aims to make its ...
Some patients taking weight-loss drugs, including popular GLP-1 treatments like Ozempic (NVO) and Wegovy, reported reducing ...
Eli Lilly said it would invest $3 billion to expand a recently acquired manufacturing facility to meet growing demand for its diabetes and weight-loss medicines. The drugmaker said the Kenosha County, ...
Eli Lilly and Company has announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical trial.